Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies

In the last decade, it has become apparent that toll-like receptor (TLR) signaling can play an important role in ovarian cancer (OC) progression. Interestingly, TLR activation in immune cells can help activate an anti-tumor response, while TLR signaling in tumor cells themselves is often associated...

Full description

Bibliographic Details
Main Authors:	Muccioli, Maria, Benencia, Fabian
Format:	Online
Language:	English
Published:	Frontiers Media S.A. 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105689/

id	pubmed-4105689
recordtype	oai_dc
spelling	pubmed-41056892014-08-06 Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies Muccioli, Maria Benencia, Fabian Immunology In the last decade, it has become apparent that toll-like receptor (TLR) signaling can play an important role in ovarian cancer (OC) progression. Interestingly, TLR activation in immune cells can help activate an anti-tumor response, while TLR signaling in tumor cells themselves is often associated with cancer-promoting inflammation. For example, it has been shown that TLR activation in dendritic cells can result in more effective antigen presentation to T cells, thereby favoring tumor eradication. However, aberrant TLR expression in OC cells is associated with more aggressive disease (likely due to recruitment of pro-tumoral leukocytes to the tumor site) and has also been implicated in resistance to mainstream chemotherapy. The delicate balance of TLR activation in the tumor microenvironment in different cell types altogether help shape the inflammatory profile and outcome of tumor growth or regression. With further studies, specific activation or repression of TLRs may be harnessed to offer novel immunotherapies or adjuvants to traditional chemotherapy for some OC patients. Herewith, we review recent literature on basic and translational research concerning therapeutic targeting of TLR pathways for the treatment of OC. Frontiers Media S.A. 2014-07-22 /pmc/articles/PMC4105689/ /pubmed/25101083 http://dx.doi.org/10.3389/fimmu.2014.00341 Text en Copyright © 2014 Muccioli and Benencia. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Muccioli, Maria Benencia, Fabian
spellingShingle	Muccioli, Maria Benencia, Fabian Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
author_facet	Muccioli, Maria Benencia, Fabian
author_sort	Muccioli, Maria
title	Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
title_short	Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
title_full	Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
title_fullStr	Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
title_full_unstemmed	Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
title_sort	toll-like receptors in ovarian cancer as targets for immunotherapies
description	In the last decade, it has become apparent that toll-like receptor (TLR) signaling can play an important role in ovarian cancer (OC) progression. Interestingly, TLR activation in immune cells can help activate an anti-tumor response, while TLR signaling in tumor cells themselves is often associated with cancer-promoting inflammation. For example, it has been shown that TLR activation in dendritic cells can result in more effective antigen presentation to T cells, thereby favoring tumor eradication. However, aberrant TLR expression in OC cells is associated with more aggressive disease (likely due to recruitment of pro-tumoral leukocytes to the tumor site) and has also been implicated in resistance to mainstream chemotherapy. The delicate balance of TLR activation in the tumor microenvironment in different cell types altogether help shape the inflammatory profile and outcome of tumor growth or regression. With further studies, specific activation or repression of TLRs may be harnessed to offer novel immunotherapies or adjuvants to traditional chemotherapy for some OC patients. Herewith, we review recent literature on basic and translational research concerning therapeutic targeting of TLR pathways for the treatment of OC.
publisher	Frontiers Media S.A.
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105689/
_version_	1613116354330624000

Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies

Similar Items